Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denise Morris

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
NPJ Systems Biology and Applications|March 19, 2024
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeuticsDaniel C Kirouac, Cole Zmurchok, Denise Morris
Intensive Care Medicine|March 10, 2016
Ten things that nurses should know about ECMOCécile Van Kiersbilck, Elizabeth Gordon, Denise Morris
Journal of AHIMA|February 28, 2009
RAC ready. How to prepare for the Recovery Audit Contractor programKathy M Johnson, Allison Bloom, Denise Morris, et al.
Pulmonary Pharmacology & Therapeutics|March 22, 2022
Comparative biochemical efficacy analysis of an alpha<sub>1</sub>-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiencyZhaoyang Li, Ryan M Franke, Denise Morris, et al.
The AAPS Journal|October 27, 2011
Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearanceDenise Morris, Joseph Podolski, Alan Kirsch, et al.
BMJ Open|May 2, 2025
Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance studyAlison Evans, Debabrata Roy, Miranda Davies, et al.
BMC Health Services Research|September 20, 2007
An evaluation of a model for the systematic documentation of hospital based health promotion activities: results from a multicentre studyHanne Tønnesen, Mette E Christensen, Oliver Groene, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|October 22, 2013
Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarinS Aubrey Stoch, Rose Witter, David Hrenuik, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2013
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal womenMatt S Anderson, Isaias Noel Gendrano, Chengcheng Liu, et al.
Drug Safety|January 14, 2026
Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus GroupFlorence van Hunsel, Samantha Lane, Dawn Cooper, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
NPJ Systems Biology and Applications|March 19, 2024
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeuticsDaniel C Kirouac, Cole Zmurchok, Denise Morris
Intensive Care Medicine|March 10, 2016
Ten things that nurses should know about ECMOCécile Van Kiersbilck, Elizabeth Gordon, Denise Morris
Journal of AHIMA|February 28, 2009
RAC ready. How to prepare for the Recovery Audit Contractor programKathy M Johnson, Allison Bloom, Denise Morris, et al.
Pulmonary Pharmacology & Therapeutics|March 22, 2022
Comparative biochemical efficacy analysis of an alpha<sub>1</sub>-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiencyZhaoyang Li, Ryan M Franke, Denise Morris, et al.
The AAPS Journal|October 27, 2011
Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearanceDenise Morris, Joseph Podolski, Alan Kirsch, et al.
BMJ Open|May 2, 2025
Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance studyAlison Evans, Debabrata Roy, Miranda Davies, et al.
BMC Health Services Research|September 20, 2007
An evaluation of a model for the systematic documentation of hospital based health promotion activities: results from a multicentre studyHanne Tønnesen, Mette E Christensen, Oliver Groene, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|October 22, 2013
Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarinS Aubrey Stoch, Rose Witter, David Hrenuik, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2013
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal womenMatt S Anderson, Isaias Noel Gendrano, Chengcheng Liu, et al.
Drug Safety|January 14, 2026
Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus GroupFlorence van Hunsel, Samantha Lane, Dawn Cooper, et al.
Pageof 2